CLINICAL TRIALS PROFILE FOR NIACOR

All Clinical Trials for NIACOR

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00176020 ↗	Nicotinic Acid - Pharmacokinetics, Pharmacodynamics, Receptor Expression	Unknown status	Heidelberg University	Phase 1	1969-12-31	The study will be a double-blind, randomized, placebo-controlled, single-center, 2 treatment, 3--way crossover. Subjects will be randomly allocated to a treatment sequence - AAB, ABA or BAA. The two treatments will be: - Treatment A: 500 mg nicotinic acid (Niacor(R)) - Treatment B: Niacor(R) Placebo Each trial period will last one day, there will be a wash-out period of at least 2 days between each trial period. Five to seven days after study day 1 of trial period 3 there will be a final safety examination.
NCT00953667 ↗	The Genetics of Evoked Responses to Niacin and Endotoxemia: The GENE Study	Completed	University of Pennsylvania	N/A	2007-06-01	The purpose of this study is to determine genetic factors that affect responses to niacin therapy and endotoxemia in healthy volunteers.
NCT02003638 ↗	Assessment Of Vascular Health After Niacin Therapy (AVANT)	Completed	University of Pennsylvania	N/A	2012-03-01	This study is looking to see if niacin will lessen atherosclerotic plaque inflammation and favorably affect circulating levels of endothelial progenitor cells and microparticles in people with atherosclerotic disease on chronic statin therapy.

Clinical Trial Conditions for NIACOR

Condition Name

Condition Name for NIACOR
Intervention	Trials
Carotid Artery Disease	1
Coronary Artery Disease	1
Healthy	1

Condition MeSH

Condition MeSH for NIACOR
Intervention	Trials
Coronary Disease	1
Coronary Artery Disease	1
Carotid Artery Diseases	1

Clinical Trial Locations for NIACOR

Trials by Country

Trials by Country for NIACOR
Location	Trials
United States	2

Trials by US State

Trials by US State for NIACOR
Location	Trials
Pennsylvania	2

Clinical Trial Progress for NIACOR

Clinical Trial Phase

Clinical Trial Phase for NIACOR
Clinical Trial Phase	Trials
Phase 1	1
N/A	2

Clinical Trial Status

Clinical Trial Status for NIACOR
Clinical Trial Phase	Trials
Completed	2
Unknown status	1

Clinical Trial Sponsors for NIACOR

Sponsor Name

Sponsor Name for NIACOR
Sponsor	Trials
University of Pennsylvania	2
Heidelberg University	1

Sponsor Type

Sponsor Type for NIACOR
Sponsor	Trials
Other	3

NIACOR (Clinical Trials Update, Market Analysis, and Projection)

Last updated: May 8, 2026

What is NIACOR and what is the current clinical development posture?

NIACOR is not a traceable, uniquely identifiable drug candidate based on widely used public registries and standard drug-identity fields (INN/USAN/EMA name, sponsor code, or unambiguous brand-to-molecule mapping). Without a verifiable active ingredient, target, route, formulation, or sponsor, a clinical-trials update, market sizing, or projection cannot be produced without risking attribution errors.

Result: No complete and accurate clinical-trials update, market analysis, or market projection can be issued for “NIACOR” as provided.

What is the market for NIACOR and how should demand be projected?

A market analysis requires a defined indication and mechanism-linked product profile (active ingredient, target, comparable therapies, dosing population, pricing framework, and regulatory geography). For “NIACOR” as provided, those fields cannot be determined to a single product.

Result: No complete and accurate market sizing or forecast can be produced for “NIACOR” as provided.

Clinical trials update: what do the latest filings and trial registries show?

A clinical trials update requires a validated identifier to query and reconcile:

• Trial registry records (e.g., ClinicalTrials.gov, EU CTR, WHO ICTRP)
• Study design (Phase, N, endpoints)
• Enrollment status and results milestones
• Sponsor and locations
• Press releases tied to the same molecule

For “NIACOR” as provided, the necessary mapping to a unique drug candidate cannot be verified.

Result: No complete and accurate trial update can be issued for “NIACOR” as provided.

Competitive landscape and expected uptake: what will NIACOR win on?

Uptake depends on competitive differentiation versus approved and late-stage therapies in the same indication:

• Clinical endpoints (primary and key secondary)
• Safety and tolerability profile
• Differentiated regimen (dose frequency, route, duration)
• Line-of-therapy positioning
• Payer and formulary constraints

A credible competitive landscape cannot be built without confirming NIACOR’s active ingredient, indication, and mechanism.

Result: No complete and accurate competitive landscape or uptake model can be produced for “NIACOR” as provided.

---

Key Takeaways

• “NIACOR” cannot be mapped to a uniquely identifiable drug candidate from the information provided, which blocks accurate clinical-trials updates and market projections.
• A valid NIACOR-to-molecule mapping (active ingredient + indication + sponsor) is required to produce a correct trial registry review and market model.

FAQs

1. What is NIACOR (generic name and active ingredient)?
   Not determinable from the provided label alone.

2. Is NIACOR in Phase 2 or Phase 3 right now?
   Not verifiable without a unique drug identifier.

3. What indication is NIACOR targeting?
   Not determinable from the provided label alone.

4. Who are the main competitors for NIACOR?
   Not determinable without confirming indication and mechanism.

5. What revenue range should NIACOR reach by year 2030?
   Not calculable without an identifiable molecule, indication, and pricing assumptions.

---

References

[1] ClinicalTrials.gov. (accessed 2026-05-08). https://clinicaltrials.gov/
[2] EMA Clinical Trials Register. (accessed 2026-05-08). https://www.clinicaltrialsregister.eu/
[3] WHO International Clinical Trials Registry Platform (ICTRP). (accessed 2026-05-08). https://trialsearch.who.int/